Home » News » CROs/Service Providers » WuXi PharmaTech acquires XenoBiotic Laboratories

WuXi PharmaTech acquires XenoBiotic Laboratories

Wednesday, October 1, 2014

CRO WuXi PharmaTech, with operations in China and the U.S., has acquired XenoBiotic Laboratories (XBL), a CRO with facilities in New Jersey and China. Financial terms have not been disclosed.

The acquisition bolsters WuXi’s Laboratory Testing Division (LTD) in bioanalytical and DMPK/ADME services, particularly in studies of radio-labeled compounds, while gaining access to new agricultural and animal health customers. The resulting expansion and enhancement of WuXi’s integrated service portfolio will accelerate the growth of LTD’s business. This acquisition expands LTD’s presence in North America, provides greater flexibility in service and support options for North American customers and presents the opportunity for further expansion.

XBL has 150 employees and operates a 45,000-square-foot research center in Plainsboro, N.J., and a 36,000-square-foot facility in Nanjing, China. The company is FDA– and USDA-registered, New Jersey-licensed for work with radioisotopes, USDEA-licensed for conducting research with Schedule 1-5 controlled substances and AAALAC-accredited.

Related Posts